 International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants TORONTO, June 9, 2021 PRNewswire - Braxia Scientific Corp. Braxia, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance the Guidelines for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression TRD. The Guidelines were developed and led by Braxias CEO Dr. Roger S. 